articles This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Article 21 hours ago - 10 mins read Computational Partnership in Small Molecule Drug Discovery The real magic happens when chemists can integrate computational models into their assay cascades, thanks to trust in their predictions. To get there, grounding computational predictions in physics and experimental reality makes all the difference. In this article, Abba E. Leffler, Ph.D. from Schrödinger tells us about: How to make computational tools like WaterMap and… Article 4 days ago - 1 min read Molecules of the Month – August 2022 A covalent KRASG12R inhibitor used as a proof-of-concept for covalent arginine modification, an oral dihydroorotate dehydrogenase inhibitor being developed for acute myelogenous leukemia, and a first-in-class YAP-TEAD protein-protein are some examples of this month’s MOTM. In the slide deck, you’ll find a compound that has over 1400-fold selectivity for Cathepsin K over other biologically relevant… Article 4 days ago - 6 mins read An Intracellular Enzyme Drug via Endocytosis: Olipudase Alfa (Xenpozyme) olipudase alfa (Xenpozyme), hydrolytic lysosomal sphingomyelin-specific enzyme, Starting dose: 0.1 mg/kg IV q2w (adults); 0.03 mg/kg IV q2w (pediatrics); Maintenance dose: 3 mg/kg IV q2w (adults); 3 mg/kg IV q2w (pediatrics), Non–central nervous system manifestations of acid sphingomyelinase deficiency, Sanofi Article 7 days ago - 6 mins read EMA Approval: Lenacapavir (Sunlenca), a First-In-Class HIV Capsid Inhibitor In August 2022, the European Medicines Agency granted Marketing Authorization to lenacapavir (Sunlenca), the first-in-class bi-annually dosed HIV capsid inhibitor indicated for multidrug-resistant HIV-1 infection. This Premium deep dive into Sunlenca includes: the industry context the clinical data the target rationale the mechanism of action and the drug’s origins. Article 7 days ago - 14 mins read Drug Discovery Technology Review: Emerging Tools and Modalities in 2022Q2/Q3 We did a deep dive into the pharmaceutical industry’s 2022Q2/Q3 news, and there’s a ton of exciting updates to share. In this review, we highlight some emerging companies, technologies, and drug discovery modalities we thought drug hunters would find interesting, including: New strategies for covalent protein modification Different methods for screening drug candidates and targets… Article 1 week ago - 6 mins read The 27 Lead Drug Molecules Acquired from Biotechs in 2021 Our team conducted a review of all the biotech acquisitions of 2021 and distilled it down to the acquisitions of drug discovery-focused biotechs. Navigate the 2021 M&A Series the top overall drug discovery M&A transactions by value (Part 1) the transactions with disclosed upfront payments (Part 2) the most valuable small molecule acquisitions (Part 3)… Pages: 1234567891011121314151617Load More
